 |
News
- January 2012: Paul Van Dun elected Chairman of the Board; Els Vanheusden becomes dedicated CEO
- December 2011: Feasibility grant approved by the agency for Innovation by Science and Technology (IWT)
- September 2011: Publication synthetic vascular graft data
- August 2011: Capricorn Health-tech Fund (CHF) invests 250 k€ and delivers interim CEO
- July 2011: Anethon incorporated
|
|
